200205018 5

21 AUG 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/74369 A1

(51) International Patent Classification[7]: A61K 31/661, A61P 35/00

(21) International Application Number: PCT/GB01/01329

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0007740.4	31 March 2000 (31.03.2000)	GB
0013928.7	8 June 2000 (08.06.2000)	GB
0014904.7	20 June 2000 (20.06.2000)	GB

(71) Applicant *(for all designated States except US)*: **ANGIOGENE PHARMACEUTICALS LTD.** [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **DAVIS, Peter, David** [GB/GB]; 14 Plowden park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB).

(74) Agent: **BRYANT, Tracey**; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

(54) Title: DIVIDED DOSE THERAPIES WITH VASCULAR DAMAGING ACTIVITY



ZD6126

(57) Abstract: The invention concerns the use of a vascular damaging agent or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human. In particular the vascular damaging agent is ZD6126, or a pharmaceutically acceptable salt thereof. The invention also relates to methods of treatment using a vascular damaging agent in divided doses.

WO 01/74369 A1

ACTION